Please assess the completion status of the following clinical trial:

Trial Title: Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Outpatient men or women aged 50 years or older~2. Must have moderate-to-severe plaque psoriasis for at least 6 months, and for whom a decision to use biologic therapy has been made, with biologic therapy planned to be initiated within the next 4-6 weeks.~3. History of varicella, or having resided in Canada for at least 30 years.~Main Exclusion Criteria:~1. Have received Varicella Zoster Vaccine vaccine or known allergies to the Varicella Zoster Vaccine vaccine or its excipients including neomycin and gelatin~2. Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukemias, lymphoma, other conditions affecting the bone marrow or lymphatic system, immunosuppression due to HIV/AIDS, cellular immune deficiencies.~3. Current use of non-topical antiviral therapy with known activity against varicella-zoster virus.~4. Exposure to varicella or zoster within 28 days prior to vaccination.~5. Patients who are diagnosed with herpes zoster at the time of the vaccination.~6. Active untreated tuberculosis.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varicella Zoster Vaccine (Type: EXPERIMENTAL): Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
- 0.9% Sodium Chloride (Type: PLACEBO_COMPARATOR): United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).